Haemonetics ( HAE) estimates, price target were boosted at Benchmark. Shares are now seen reaching $49. New analyst also raised estimates, as the company has premium pricing power, Benchmark said. Buy rating. LVS) price target was raised at J.P. Morgan to $72. Multiple positive near-term and longer-term catalysts, J.P. Morgan said. Overweight rating. Merck ( MRK) estimates were increased at BMO Capital through 2014. Company has a solid pipeline, and Januvia can continue to growth, BMO Capital said. Market Perform rating and $50 price target. M&T Bank ( MTB) numbers were cut at BMO Capital. Shares are now seen reaching $121. Estimates were also reduced, given the company's new guidance, BMO Capital said. Market Perform rating. Noble ( NE) estimates were raised at UBS. Reflect five new jackup contracts, said UBS. Price target is $41. Oasis Petroleum ( OAS) numbers were increased at Sterne Agee. Estimates were boosted through 2015. Recent acquisition should add to earnings, Sterne Agee said. Buy rating and new $54 price target. Palo Alto ( PANW) numbers were raised at BMO Capital. Shares are now seen reaching $50. Estimates were also increased, given better license and billings growth, BMO Capital said. Market Perform rating. Raytheon ( RTN) estimates, price target were increased at Jefferies. Estimates were raised through 2014. Company is gaining market share and can continue to grow overseas, Jefferies said. Buy rating and new $87 price target. Zoetis ( ZTS) was added to the US 1 List at Bank of America/Merrill Lynch. Profit margin acceleration story is underappreciated by the market, BofA/Merrill said. $36 price target. >To submit a news tip, email: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.